Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProMetic BioSciences, the therapeutic unit of ProMetic Life, has received authorization from Health Canada to begin a phase Ib/II clinical trial of PBI-1402, its novel therapeutic compound in development to treat patients with anemia.
Subscribe to our email newsletter
The company plans to study the safety and efficacy of PBI-1402 in up to 30 cancer patients undergoing chemotherapy and suffering from anemia.
This clinical trial will be undertaken at Maisonneuve-Rosemont Hospital, in Montreal, under the supervision of Drs Denis-Claude Roy (hematologist) and Julie Beaudet (oncologist). “Following the results obtained during the phase I trial, displaying an excellent safety profile and an increase of reticulocyte numbers, we are very excited to initiate this phase Ib/II study in chemotherapy-treated patients”, said Dr Denis-Claude Roy.
In addition, ProMetic scientists have made significant progress towards the elucidation of the mechanism of action of PBI-1402. This important step will support future clinical development strategies for this candidate drug.
The mechanism of action of PBI-1402 is different from the current drug of choice for the treatment of anemia, erythropoietin (EPO). As such, PBI-1402 offers the potential to treat anemic patients who are not responsive to EPO.
Furthermore, since PBI-1402 has shown an additive effect in combination with EPO on human progenitor cell proliferation in vitro, it could be used in monotherapy and/or in combination with EPO.